CLINICAL VALUE OF COMBINING 18F-FDG PET/CT SCANNING WITH SERUM LEVELS OF CYFRA21- 1 AND HIF-1ΑFOR EARLY DETECTION OF LUNG CANCER

YING ZHANG LEI QIN, CHANGMING ZHANG

Department of Imaging, Liaocheng Peoples’ Hospital

Objective: To explore the value of combining 2-Fluoro-2-Deoxy-D-Glucopyranose (18F-FDG) (Positron emission tomo- graphy/computer tomography, PET/CT) scanning with serum levels of (Cytokeratin 19 fragment antigen), Cyfra21-1 and (hypoxia inducible factor-1α, HIF-1α) αfor early detection of lung cancer.

Method: A total of 80 treatment-free patients with lung cancer confirmed through imaging, chemical pathology diagnosis and cytology in our hospital from January 2015 to December 2016 were placed in the early lung cancer group, while 25 others with beni- gn lung diseases who reported in our hospital during the same period were placed in the control group. Serum levels of Cyfra21-1 and HIF-1α in both groups were quantified, and then 18F-FDG PET/CT scanning was done, so as to evaluate the clinical significan- ce of both methods in early diagnosis of lung cancer.In a third approach, tissue levels of deoxyglucose and serum levels of Cyfra21-1 and HIF-1α were determined simultaneouslyusing18F-FDG PET/CT scanning.

Results: The scan revealed that the standard uptake value (SUV) of 80 patients with early lung cancer (10.51±4.23) was signi- ficantly higher than that of the control group (P <0.01). Levels of Cyfra21-1 and HIF-1α were also significantly higher than in the control group (P <0.01), and also significantly higher in patients with squamous cell carcinoma than in those with adenocarcinoma or small cell carcinoma (P <0.05). However, there were no significant differences in Cyfra21-1 and HIF-1α levels amongadenocarci- noma, small cell carcinoma and unclassified cancerpatients (P>0.05). The sensitivity, specificity, and accuracy of Cyfra21-1 inde- pendently determined were 60.53%, 90.34%, and 80.52%, respectively, while those of HIF-1α were 49.56%, 84.91%, and 65.23% respectively. The sensitivity, specificity, and accuracy of 18F-FDG PET/CTindependently determined were 88.75%, 90.57%, and 90.05% respectively, while those of 18F-FDG PET/CT determined jointly with Cyfra21-1 and HIF-1α were 97.04%, 98.62%, and 98.75%, respectively. There was statistical difference between the values of the independent and combined determinations (P <0.05) .

Conclusion: The technique of combining 18F-FDG PET/CT scanning with determination of serum Cyfra21-1 and HIF-1α levels is a considerably improved, accurate and sensitive approach for diagnosis of early stages of lung cancer.